What caused the SBX.DE stock drop today?

The intraday fall to €2.60 reflects weak short-term liquidity, larger-than-normal selling volume of 21,451.00 shares, and concern over negative earnings metrics such as EPS -2.24 and current ratio 0.81.

What is the Meyka AI view on SBX.DE stock?

Meyka AI gives SBX.DE a score of 61.83/100 (Grade B, HOLD). The model highlights mixed fundamentals and a model-based yearly forecast of €4.01, with a 54.16% implied upside from €2.60.

Is SBX.DE stock a value or a growth play?

SynBiotic sits in healthcare as an early-stage specialty drug maker. Valuation shows a price-to-book near 0.99 but losses on the income statement, making it a speculative growth play with value-like balance-sheet caveats.

What should traders watch next for SBX.DE stock?

Monitor intraday volume, bid-ask spreads, the 50-day and 200-day averages (€2.33 and €2.88), and any news around product development or funding that could change liquidity and sentiment.

DE Stocks

SBX.DE SynBiotic SE (XETRA) down 17.59% intraday: watch cash runway

ByHuzaifa Zahoor January 9, 2026January 9, 2026

SBX.DE stock fell 17.59% intraday on XETRA to €2.60 on 09 Jan 2026, marking it among today’s top losers. Volume jumped to 21,451.00 shares versus an average of 7,639.00, signalling active selling. The drop follows weak near-term liquidity metrics and continued losses on the income statement. Traders should note SynBiotic SE’s current market cap of €18,722,487.00 and a trailing EPS of -2.24, which tie company fundamentals to the intraday sell-off.